Welcome to the new version of CaltechAUTHORS. Login is currently restricted to library staff. If you notice any issues, please email coda@library.caltech.edu
Published July 15, 2005 | Published
Journal Article Open

Disruption of fusion results in mitochondrial heterogeneity and dysfunction


Mitochondria undergo continual cycles of fusion and fission, and the balance of these opposing processes regulates mitochondrial morphology. Paradoxically, cells invest many resources to maintain tubular mitochondrial morphology, when reducing both fusion and fission simultaneously achieves the same end. This observation suggests a requirement for mitochondrial fusion, beyond maintenance of organelle morphology. Here, we show that cells with targeted null mutations in Mfn1 or Mfn2 retained low levels of mitochondrial fusion and escaped major cellular dysfunction. Analysis of these mutant cells showed that both homotypic and heterotypic interactions of Mfns are capable of fusion. In contrast, cells lacking both Mfn1 and Mfn2 completely lacked mitochondrial fusion and showed severe cellular defects, including poor cell growth, widespread heterogeneity of mitochondrial membrane potential, and decreased cellular respiration. Disruption of OPA1 by RNAi also blocked all mitochondrial fusion and resulted in similar cellular defects. These defects in Mfn-null or OPA1-RNAi mammalian cells were corrected upon restoration of mitochondrial fusion, unlike the irreversible defects found in fzo yeast. In contrast, fragmentation of mitochondria, without severe loss of fusion, did not result in such cellular defects. Our results showed that key cellular functions decline as mitochondrial fusion is progressively abrogated.

Additional Information

© 2005 The American Society for Biochemistry and Molecular Biology, Inc. Received for publication, March 21, 2005; published, JBC Papers in Press, May 17, 2005. We are grateful to Drs. G. Hernandez-Hoyos, J. Ila-Alberola, J. Rossi, L. Griparic, and A. van der Bliek for generous gifts of plasmids and antibody. We thank Dr. J. Pomerantz for useful advice on RNAi.

Attached Files

Published - CHEjbc05.pdf


Files (493.7 kB)
Name Size Download all
493.7 kB Preview Download

Additional details

August 22, 2023
August 22, 2023